# US 2008/0187568 A1 · Polymerization with precipitation of proteins for elution in physiological solution

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187568 A1
- Document ID: US20080187568A1
- Status: Published application
- Kind: A1
- Application number: 12/012,808
- Filed: 2008-02-06
- Published: 2008-08-07
- Earliest claimed: 2007-02-06
- Inventors: Amarpreet S. Sawhney
- Web page: https://patentgrep.com/patent/US20080187568A1

## CPC

- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 38/1875: {Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor}
- A61K 38/363: {Fibrinogen}
- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods and compositions for polymerizing materials with the process of making the material causing precipitation of an agent that is subsequently released by the material. In some aspects, controlled delivery of bioactive substances from biodegradable hydrogels is disclosed. In certain embodiments, biodegradable hydrogels formed in situ comprise entrapped precipitated proteins that are ordinarily water soluble. The dissolving and release of the bioactive substance is impeded by the hydrogel structure and takes place at a slow rate, thus controlling the release of said bioactive substance from the hydrogel. Thus a bioactive substance that would normally be rapidly dissolved in a physiological surrounding is, instead, released in a controlled manner. The hydrogel phase also serves to protect the bioactive agent from cells and enzymes present in physiological surroundings.

## Claims

### Claim 1

A method for forming a crosslinked polymer hydrogel comprising:
mixing a solution that comprises a medicinal agent dissolved in a water miscible solvent with a water soluble precursor to form a mixture and simultaneously precipitate the medicinal agent;
depositing the mixture at a location exposed to a physiological fluid; and
polymerizing the precursor to form the crosslinked hydrogel, entrap the precipitated agent, and subsequently gradually release the agent into the physiological fluid.

### Claim 2 (depends on 1)

The method of claim 1 wherein the solution is aqueous and the precursor causes the precipitation of the medicinal agent.

### Claim 3 (depends on 2)

The method of claim 2 wherein the precipitation is performed by a volume exclusion mechanism.

### Claim 4 (depends on 3)

The method of claim 3 wherein the precursor comprises polyethylene oxide.

### Claim 5 (depends on 1)

The method of claim 1 wherein the solution is aqueous and the precipitation is caused by a changing a member of the group consisting of salt concentration, ion content, pH, and a combination thereof.

### Claim 6 (depends on 5)

The method of claim 5 wherein the solution is aqueous and a salt is mixed into the mixture at a concentration that causes the precipitation of the medicinal agent by a salting-out effect.

### Claim 7 (depends on 5)

The method of claim 5 wherein the solution is aqueous and a buffer is mixed into the mixture at a concentration and pH that causes the precipitation of the medicinal agent by a change in pH.

### Claim 8 (depends on 1)

The method of claim 1 wherein the water miscible solvent comprises alcohol or an organic solvent and the precipitation is performed by dilution of the alcohol or organic solvent with a second solvent that is aqueous.

### Claim 9 (depends on 1)

The method of claim 1 wherein the water miscible solvent comprises alcohol or organic solvent and the precipitation is performed by removal of the alcohol or organic solvent.

### Claim 10 (depends on 1)

The method of claim 1 wherein the precursor is a first precursor that comprises nucleophilic functional groups and is mixed with a second precursor that comprises electrophilic groups that undergo covalent bonding with the nucleophilic functional groups to achieve the polymerization.

### Claim 11 (depends on 1)

The method of claim 1 wherein the precursor is a first precursor that comprises unsaturated functional groups and is mixed with a polymerization initiator that initiates the polymerization.

### Claim 12 (depends on 1)

The method of claim 1 wherein the hydrogel is formed from two precursors that react with each other to form covalent bonds and the polymerization is initiated by mixing the two precursors.

### Claim 13 (depends on 1)

The method of claim 1 wherein the precursor comprises polyalkylene oxide, polyether, polyethylene glycol, dextran, polyvinyl pyrrolidinone, or a copolymer thereof having at least about 40% by molecular weight of the polyalkylene oxide, the polyether, the polyethylene glycol, the dextran, or the polyvinyl pyrrolidinone.

### Claim 14 (depends on 1)

The method of claim 1 wherein the medicinal agent is water soluble.

### Claim 15

A medical device comprising a crosslinked material adhesive to and conformal to a tissue of a patient that comprises a precipitated medicinal agent soluble in a physiological solution available at the tissue.

### Claim 16 (depends on 15)

The medical device of claim 15 wherein the precursor comprises polyethylene oxide.

### Claim 17 (depends on 15)

The medical device of claim 15 wherein the material is a hydrogel.

### Claim 18 (depends on 17)

The medical device of claim 17 wherein the hydrogel comprises a salt, buffer, alcohol, or organic solvent at a concentration effective to precipitate the bioactive substance.

### Claim 19 (depends on 17)

The medical device of claim 17 wherein the hydrogel comprises a polymerization reaction product of a first precursor that comprises nucleophilic functional groups and a second precursor that comprises electrophilic groups that undergo covalent bonding with the nucleophilic functional groups to achieve the polymerization.

### Claim 20 (depends on 17)

The medical device of claim 17 wherein the first precursor comprises polyalkylene oxide, polyether, polyethylene glycol, dextran, polyvinyl pyrrolidinone, or a copolymer thereof having at least about 40% by molecular weight of the polyalkylene oxide, the polyether, the polyethylene glycol, the dextran, or the polyvinyl pyrrolidinone.

### Claim 21 (depends on 15)

The method of claim 15 wherein the medicinal agent is water soluble.
